SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong1/23/2025 1:07:47 PM
1 Recommendation

Recommended By
Return to Sender

   of 7980
 
Life sciences stocks fall on NIH funding concerns

Jan. 23, 2025 12:55 PM ET
By: Val Brickates Kennedy, SA News Editor

Grandbrothers/iStock Editorial via Getty Images

Life sciences stocks were in retreat Thursday after the news outlet Science reported that newly imposed restrictions on the National Institutes of Health by the Trump administration have stoked concerns in the research community about future support.

Shares of 10x Genomics (NASDAQ: TXG) and Pacific Biosciences of California (NASDAQ: PACB), also known as PacBio, both fell 10%, while Illumina (NASDAQ: ILMN) and Bio-Rad ( BIO) shares fell 5% and 4%, respectively. Shares of Qiagen ( QGEN) and Bruker ( BRKR) slid 3%, with shares of Thermo Fisher Scientific ( TMO), Charles River Laboratories ( CRL) and Revvity ( RVTY) slipping 1%.

Late Wednesday, Science reported that the incoming administration had already imposed a "wide range of restrictions" on the NIH, including the cancellation of grant review meetings.

“The impact of the collective executive orders and directives appears devastating,” one senior NIH employee told Science.

In a note released Thursday, UBS said the new administration and both chambers of Congress had "appetite to reform the NIH."

"We expect the NIH budget to be flat to declining in the next few years and ex-U.S. academic funding to be muted as well. The newly imposed restrictions are consistent with our cautious view," UBS added.

UBS said that in its area of coverage, genomics companies 10x (NASDAQ: TXG), PacBio (NASDAQ: PACB) and Illumina (NASDAQ: ILMN) were the most exposed to potential cuts in U.S. academic/government spending.

UBS added that 10x ( TXG) and PacBio ( PACB) had greater than 20% exposure to the NIH budget and that it expected 2025 to be "a challenging year" for genomic technology companies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News